T
Takasuke Mukaiyama
Researcher at Tohoku University
Publications - 20
Citations - 489
Takasuke Mukaiyama is an academic researcher from Tohoku University. The author has contributed to research in topics: Enantioselective synthesis & Organocatalysis. The author has an hindex of 11, co-authored 20 publications receiving 427 citations. Previous affiliations of Takasuke Mukaiyama include Pfizer & Tokyo University of Science.
Papers
More filters
Journal ArticleDOI
One-pot synthesis of (-)-oseltamivir and mechanistic insights into the organocatalyzed Michael reaction
Takasuke Mukaiyama,Takasuke Mukaiyama,Hayato Ishikawa,Hayato Ishikawa,Hiroyuki Koshino,Yujiro Hayashi,Yujiro Hayashi +6 more
TL;DR: Investigation into the effect of acid demonstrated that an acid additive accelerates not only the E-Z isomerization of the enamines derived from pentan-3-yloxyacetaldehyde with diphenylprolinol silyl ether, but also ring opening of the cyclobutane intermediate and the addition reaction of theEnamine to (Z)-N-2-nitroethenylacetamide.
Journal ArticleDOI
Stoichiometric Reactions of Enamines Derived from Diphenylprolinol Silyl Ethers with Nitro Olefins and Lessons for the Corresponding Organocatalytic Conversions – a Survey
Dieter Seebach,Xiaoyu Sun,Marc-Olivier Ebert,W. Bernd Schweizer,Nirupam Purkayastha,Albert K. Beck,J. Duschmalé,Helma Wennemers,Takasuke Mukaiyama,M. Benohoud,Yujiro Hayashi,Markus Reiher +11 more
TL;DR: In this paper, the stoichiometric reactions of enamines prepared from aldehydes and diphenyl-prolinol silyl ethers with nitro olefins have been investigated.
Journal ArticleDOI
Asymmetric total synthesis of (-)-azaspirene, a novel angiogenesis inhibitor.
Yujiro Hayashi,Mitsuru Shoji,Junichiro Yamaguchi,Kenji Sato,Shinpei Yamaguchi,Takasuke Mukaiyama,Ken Sakai,Yukihiro Asami,Hideaki Kakeya,Hiroyuki Osada +9 more
TL;DR: The asymmetric total synthesis of (-)-azaspirene, an angiogenesis inhibitor, has been accomplished, establishing its absolute stereochemistry.
Journal ArticleDOI
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.
Peter Jones,R. Ian Storer,Yogesh A. Sabnis,Florian Wakenhut,Gavin A. Whitlock,Katherine S. England,Takasuke Mukaiyama,Christoph Martin Dehnhardt,Jotham Wadsworth Coe,Steve Kortum,Jill Chrencik,David G. Brown,Rhys M. Jones,John Murphy,Thean Yeoh,Paul Morgan,Iain Kilty +16 more
TL;DR: A potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode and optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan- JAK inhibitor 2, which was advanced into clinical studies.
Journal ArticleDOI
Asymmetric total synthesis of pseurotin A.
Yujiro Hayashi,Mitsuru Shoji,Shinpei Yamaguchi,Takasuke Mukaiyama,Junichiro Yamaguchi,Hideaki Kakeya,Hiroyuki Osada +6 more
TL;DR: The asymmetric total syntheses of pseurotin A and 8-O-demethylpseurotin B have been accomplished and key reactions are a NaH-promoted intramolecular cyclization of an alkynylamide to form a gamma-lactam and the late-stage introduction of the benzoyl group.